title: Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.
abstract: We describe 4 consecutive hypertensive women with polycystic ovary syndrome, classified according to the National Institute of Child Health and Human Development (NICHD) criteria, treated with telmisartan 40 mg/d for six months. Blood pressure, menstrual pattern, body mass index (BMI), homeostasis model assessment of insulin resistance, testosterone, dehydroepiandrosterone sulfate (DHEAS), and androstenedione were recorded and measured before and after telmisartan treatment. Obese hypertensive polycystic ovary syndrome patients had a decrease in systolic blood pressure. Marked drop-off in serum androgen concentrations was observed in all four patients. Three patients improved their menstrual cyclicity. The improvements were independent of changes in weight. The reduction of androgen concentrations and improvement in menstrual pattern was achieved despite a non-significant change of fasting insulin levels in patients, who were not considered severely insulin resistant at baseline. These findings may provide a new basis for a proper choice of the antihypertensive drug in hypertensive women with polycystic ovary syndrome.
authors: Department of Endocrinology, Diabetes, and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska 7, 1525 Ljubljana, Slovenia. mojcajensterle@yahoo.com
authors: Mojca
authors: M
authors: Jensterle
authors: Andrej
authors: A
authors: Janez
authors: Bojan
authors: B
authors: Vrtovec
authors: Helena
authors: H
authors: Meden-Vrtovec
authors: Marija
authors: M
authors: Pfeifer
authors: Janez
authors: J
authors: Prezelj
authors: Tomaz
authors: T
authors: Kocjan
mesh_terms: D000328:Adult; D000728:Androgens / Q000097:blood*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D005215:Fasting; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008598:Menstruation / Q000502:physiology*; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D001786:Blood Glucose; D000077333:Telmisartan